Cargando…

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma

Mucinous epithelial ovarian cancer (mEOC) is a rare subset of epithelial ovarian cancer. When diagnosed at a late stage, its prognosis is very poor, as it is quite chemo-resistant. To find new therapeutic options for mEOC, we performed high-throughput screening using a siRNA library directed against...

Descripción completa

Detalles Bibliográficos
Autores principales:	Affatato, Roberta, Carrassa, Laura, Chilà, Rosaria, Lupi, Monica, Restelli, Valentina, Damia, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140026/ https://www.ncbi.nlm.nih.gov/pubmed/32183025 http://dx.doi.org/10.3390/cancers12030672

Ejemplares similares

Recent Insights into Mucinous Ovarian Carcinoma
por: Ricci, Francesca, et al.
Publicado: (2018)

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
por: Restelli, Valentina, et al.
Publicado: (2015)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Therapeutic options for mucinous ovarian carcinoma☆
por: Gorringe, Kylie L., et al.
Publicado: (2020)

U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint
por: Carrassa, Laura, et al.
Publicado: (2009)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
por: Chiappa, Michela, et al.
Publicado: (2022)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models()()
por: Guffanti, Federica, et al.
Publicado: (2016)

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer
por: Ubezio, Paolo, et al.
Publicado: (2016)

Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
por: Wang, Fujun, et al.
Publicado: (2023)

Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment
por: Wang, Yicong, et al.
Publicado: (2023)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Role of magnetic resonance imaging in the differentiation of mucinous ovarian carcinoma and mucinous borderline ovarian tumors
por: Hasbay, Ebru, et al.
Publicado: (2023)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Retrospective study of characteristics and hyperthermia intraperitoneal perfusion in mucinous borderline ovarian tumor and mucinous ovarian carcinoma
por: He, Xiaoli, et al.
Publicado: (2023)

The molecular origin and taxonomy of mucinous ovarian carcinoma
por: Cheasley, Dane, et al.
Publicado: (2019)

Profiling the immune landscape in mucinous ovarian carcinoma
por: Meagher, Nicola S., et al.
Publicado: (2023)

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
por: Serpico, Angela Flavia, et al.
Publicado: (2019)

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary
por: Simons, Michiel, et al.
Publicado: (2019)

Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials
por: Nugawela, Devindee, et al.
Publicado: (2023)

Prognostic similarity between ovarian mucinous carcinoma with expansile invasion and ovarian mucinous borderline tumor: A retrospective analysis
por: Hada, Taira, et al.
Publicado: (2021)

Ovarian mucinous cystadenoma with mural nodule of anaplastic carcinoma.
por: Hong, S. R., et al.
Publicado: (1998)

Prognosis in primary mucinous ovarian carcinoma: focusing on the five pathological findings indicating metastatic mucinous carcinoma to the ovary
por: Lee, Sang won, et al.
Publicado: (2021)

Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment
por: Maresca, Luisa, et al.
Publicado: (2022)

Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy
por: Lee, Dong-Hee, et al.
Publicado: (2021)

Genome-wide significant risk associations for mucinous ovarian carcinoma
por: Kelemen, Linda E., et al.
Publicado: (2015)

Identification of the PLK2-Dependent Phosphopeptidome by Quantitative Proteomics
por: Franchin, Cinzia, et al.
Publicado: (2014)

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms
por: Lee, Yi-Ju, et al.
Publicado: (2016)

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
por: Ryland, Georgina L., et al.
Publicado: (2015)

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
por: Hollis, Robert L., et al.
Publicado: (2021)

Surgical staging of apparent early-stage ovarian mucinous carcinoma
por: Yuan, Zhen, et al.
Publicado: (2022)

Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma
por: Ma, Huan, et al.
Publicado: (2021)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis
por: Hada, Taira, et al.
Publicado: (2023)

Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics
por: Gao, Yang, et al.
Publicado: (2021)

Retrospective Study of the Epidemiology, Pathology, and Therapeutic Management in Patients With Mucinous Ovarian Tumors
por: Zhang, Yuanyuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3g5a21misa6t9h0hpojdfdtbvb